Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 16, 2017. The document serves as a transaction notification regarding insider trading activities involving Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them (PCA), rather than a financial results report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $42.00 per ADS.
- Transaction Volume: 4 ADSs and 91 ADSs in separate transactions.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details two specific increases in ADS holdings resulting from the revaluation of the cash element of notional investments within the GSK 401(K) plan on March 15, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of share allocations.
Key Facts for Investor Verification
- Transaction Date: March 15, 2017.
- Parties Involved: Dr. M M Slaoui (Chairman, Global Vaccines) and Dr. K Slaoui (PCA of Dr. M M Slaoui).
- Nature of Transaction: Notional allocation of ADSs via the GSK 401(K) plan revaluation.
- Volume Acquired: 4 ADSs by Dr. M M Slaoui and 91 ADSs by Dr. K Slaoui.
- Price: $42.00 per ADS for both transactions.